MaxCyte, Inc. MaxCyte to Present at BIO CEO & Investor Conf
05 February 2020 - 6:00PM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
05 February 2020
FOR IMMEDIATE RELEASE
MaxCyte's CEO to Present Update on Life Sciences Business &
First-in-class
CARMA(TM) Cellular Therapies at BIO CEO & Investor
Conference in New York
Gaithersburg, Maryland - 5 February 2020 - MaxCyte, the global
cell-based therapies and life sciences company, announces its
planned participation at the BIO CEO & Investor Conference at
the New York Marriott Marquis. CEO & President Doug Doerfler
will present Monday, 10 February at 2:30 p.m. ET (Odets Room) on
how MaxCyte is driving the development of the next generation of
cell-based therapies through its ExPERT(TM) instrument family,
supporting its Life Sciences Business, and with its proprietary
CARMA platform.
The ExPERT instrument family represents the next generation of
the industry's leading, clinically validated, electroporation
technology for complex and scalable cellular engineering. By
delivering high transfection efficiency with enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics and provides a single discovery and
development platform from concept to clinical development to
commercialization. In 2019, the Company signed five
clinical/commercial licenses with partners including Kite (Gilead),
Editas Medicine, Vor Biopharma and KSQ Therapeutics, and now has
more than 100 cell therapy programmes under license of which more
than 70 are licensed for clinical use.
CARMA Cellular Therapies is developing its novel and proprietary
technology for non-viral, human messenger RNA (mRNA)-based,
chimeric antigen receptor (CAR) or T-cell receptor (TCR) redirected
immune cell therapies for solid cancer and offers the potential for
a safer cell therapy, as a result of transient expression of
receptor(s) and a non-viral delivery approach. MaxCyte recently
established its CARMA program as a wholly owned subsidiary to
facilitate independent investment and new partnerships to advance
the CARMA platform.
For a meeting with MaxCyte's CEO at the conference please
contact Sheila Tiffany at sheilat@maxcyte.com.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. Through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
technology worldwide, including with all of the top ten global
biopharmaceutical companies. The Company now has more than 100
partnered programme licenses in cell therapy with more than 70
licensed for clinical use. The Company has now signed eight
clinical/commercial licenses with leading cell therapy developers
and the potential pre-commercial milestones from these
relationships now exceeds $650 million. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. MaxCyte is also developing novel CARMA
therapies, with its first drug candidate in a Phase I clinical
trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic
platform for autologous cell therapy for the treatment of solid
cancers. MaxCyte has established CARMA as a wholly owned subsidiary
to facilitate independent investment and new partnerships to
advance the CARMA platform. For more information, visit
www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
US Media Relations +1 410 299 3310
Jamie Lacey-Moreira jamielacey@presscommpr.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUPUBUPUPUPPC
(END) Dow Jones Newswires
February 05, 2020 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024